ERBB2 and breast cancer: In multivariate logistic regression analysis, Garcia-Martinez et al. (2014) confirmed an independent predictive value of a high baseline CD20+ TIL population for improved pCR (p = 0.005) [37] among a cohort of 108 patients comprising a mix of TNBC, HER2-enriched and luminal breast cancers.